ClinConnect ClinConnect Logo
Search / Trial NCT06480084

Prevalence of EILO Among Children With Asthma

Launched by MEDISCH SPECTRUM TWENTE · Jun 26, 2024

Trial Information

Current as of July 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how common Exercise Induced Laryngeal Obstruction (EILO) is among children who have asthma. EILO can make it hard for kids to breathe during exercise, and researchers believe it may occur more often in children with asthma than in the general population. The study aims to find out if about 15% of young asthma patients experience EILO, compared to just 5-8% in teens without asthma.

To participate, children aged 12 to 18 who have been diagnosed with asthma by a doctor may be eligible. They should have shown specific asthma symptoms within the last two years, such as a significant drop in lung function after exercise. Participants will take part in an exercise test, during which doctors will monitor their breathing and ask them questions about their asthma control and breathing difficulties. It’s important to note that those with other serious lung diseases or recent asthma flare-ups won’t be eligible for this study. This research could help improve understanding and treatment for young asthma patients who struggle with breathing during physical activity.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 12 to 18 years
  • Paediatrician diagnosed asthma confirmed with at least one of the following during the last two years: Positive ECT (post-exercise fall in FEV1 \> 10%) / Positive methacholine test (PC20 value of ≤8 mg/mL) / Bronchodilator reversibility (increase in FEV1 ≥12% and/or ≥200 mL following inhalation of 200-400 μg short-acting β2-agonists)
  • Exclusion Criteria:
  • Other severe cardiopulmonary disease
  • Inability to perform ECT or CLE test
  • Inability to perform technically acceptable spirometry
  • Asthma exacerbation or respiratory tract infection in the last 2 weeks
  • Short-acting β2-agonists or long-acting β2-agonists use less than respectively 8 and 24 hours before the ECT or CLE test
  • Oral corticosteroid use in the 4 weeks before the ECT or CLE test

About Medisch Spectrum Twente

Medisch Spectrum Twente (MST) is a leading healthcare institution located in the Netherlands, dedicated to providing high-quality medical care and advancing clinical research. As a regional hospital, MST is committed to improving patient outcomes through innovative treatment options and comprehensive clinical trials. The institution fosters collaboration among multidisciplinary teams of healthcare professionals, researchers, and academic partners, ensuring a robust environment for conducting research that adheres to the highest ethical standards. MST's focus on patient-centered care and its strategic initiatives in clinical research contribute significantly to the advancement of medical knowledge and the development of effective therapies.

Locations

Enschede, Overijssel, Netherlands

Patients applied

0 patients applied

Trial Officials

Vera Hengeveld, MD

Principal Investigator

Medisch Spectrum Twente

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported